硝苯地平控释片治疗轻中度高血压的疗效及药理研究

Efficacy and pharmacological study of nifedipine controlled release tablets in the treatment of mild to moderate hypertension

目的探析硝苯地平控释片在轻中度高血压患者中的治疗效果及药理作用。方法 300例轻中度高血压患者为研究对象,根据治疗方法不同分为对照组及观察组,各150例。对照组患者应用非洛地平治疗,观察组患者应用硝苯地平控释片治疗。对比两组患者的治疗效果、血压水平、不良反应发生情况。结果观察组总有效率为99.33%,对照组总有效率为96.00%,比较差异无统计学意义(P>0.05)。治疗前,两组患者的收缩压、舒张压比较,差异均无统计学意义(P>0.05);治疗4周后,两组患者的收缩压、舒张压均较本组治疗前降低,差异具有统计学意义(P<0.05);但组间治疗4周后比较,差异均无统计学意义(P>0.05)。观察组不良反应发生率3.33%低于对照组的9.33%,差异具有统计学意义(P<0.05)。结论非洛地平和硝苯地平控释片在轻中度高血压治疗中的疗效相当,但硝苯地平控释片的不良反应较少,用药安全性较高,值得临床推广应用。

Objective To discuss and analyze the treatment effect and pharmacological effect of nifedipine controlled release tablets in the treatment of mild to moderate hypertension. Methods A total of 300 patients with mild to moderate hypertension as study subjects were divided by different treatment methods into control group and observation group, with 150 cases in each group. The control group was treated with felodipine, and the observation group was treated with nifedipine controlled release tablets. Comparison was made on treatment effect, blood pressure level and occurrence of adverse reactions between the two groups. Results The observation group had total effective rate as 99.33%, and the control group had total effective rate as 96.00%. The difference was not statistically significant (P>0.05). Before treatment, there was no statistically significant difference in systolic blood pressure and diastolic blood pressure between the two groups (P>0.05). After 4 weeks of treatment, both groups had lower systolic blood pressure and diastolic blood pressure than those before treatment, and their difference was statistically significant (P<0.05). There was no significant difference between the two groups after 4 weeks of treatment (P>0.05). The observation group had lower incidence of adverse reactions as 3.33% than 9.33% in the control group, and the difference was statistically significant (P<0.05). Conclusion The efficacy of felodipine and nifedipine controlled-release tablets is comparable in the treatment of mild to moderate hypertension, but the adverse reactions of nifedipine controlled-release tablets are less and its medication safety is higher. It is worthy of clinical promotion and application.